|NASDAQ: AGLE||Healthcare / Biotechnology / USA|
|0.3300||+0.0045||+1.38%||Vol 57.77K||1Y Perf -87.72%|
|Mar 22nd, 2023 14:19 DELAYED|
|-0.03 -7.74%||- -|
|Target Price||1.88||Analyst Rating||Moderate Buy 1.80|
|Potential %||469.70||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/100/100||Value Ranking||★★★ 51.74|
|Insiders Value % 3/6/12 mo.||-/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||1.05||Earnings Rating||Strong Buy|
|Market Cap||21.58M||Earnings Date||4th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|-38 174 500.00|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2023|
|Estimated EPS Next Report||-0.20|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||257.89K|
|Avg. Monthly Volume||231.71K|
|Avg. Quarterly Volume||329.81K|
Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock closed at 0.3255 per share at the end of the most recent trading day (a 8.5% change compared to the prior day closing price) with a volume of 197.61K shares and market capitalization of 21.58M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 87 people. Aeglea BioTherapeutics Inc. CEO is Anthony G. Quinn.
The one-year performance of Aeglea BioTherapeutics Inc. stock is -87.72%, while year-to-date (YTD) performance is -27.65%. AGLE stock has a five-year performance of -96.9%. Its 52-week range is between 0.3 and 3.17, which gives AGLE stock a 52-week price range ratio of 1.05%
Aeglea BioTherapeutics Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.46, a price-to-sale (PS) ratio of 14.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.45%, a ROC of -95.69% and a ROE of -100.73%. The company’s profit margin is -%, its EBITDA margin is -1 455.10%, and its revenue ttm is $2.16 Million , which makes it $0.04 revenue per share.
Of the last four earnings reports from Aeglea BioTherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Aeglea BioTherapeutics Inc.’s next earnings report date is 04th May 2023.
The consensus rating of Wall Street analysts for Aeglea BioTherapeutics Inc. is Moderate Buy (1.8), with a target price of $1.88, which is +469.70% compared to the current price. The earnings rating for Aeglea BioTherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aeglea BioTherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aeglea BioTherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.81, ATR14 : 0.05, CCI20 : -127.71, Chaikin Money Flow : -0.36, MACD : -0.04, Money Flow Index : 36.12, ROC : -17.39, RSI : 36.56, STOCH (14,3) : 15.94, STOCH RSI : 1.00, UO : 30.77, Williams %R : -84.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aeglea BioTherapeutics Inc. in the last 12-months were: Marcio Souza (Buy at a value of $50 472), Michael Conick Hanley (Buy at a value of $20 022)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Moderate Buy|
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.
CEO: Anthony G. Quinn
Telephone: +1 512 942-2935
Address: 805 Las Cimas Parkway, Austin 78746, TX, US
Number of employees: 87
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.